Lithium and cannabis do not interact through the same liver enzymes, so there is no classic drug-drug interaction of the kind you see with many psychiatric medications. That might sound reassuring, but it leaves out the bigger picture. The real risks of smoking weed while taking lithium are indirect and, in some cases, serious: dehydration and vomiting that can push lithium into toxic territory, worsening of the very mood symptoms lithium is prescribed to control, and a well-documented pattern of people on lithium becoming less consistent with their medication when they use cannabis regularly.
Why Lithium’s Narrow Therapeutic Window Matters Here
Lithium is unusual among psychiatric medications. The dose that works is uncomfortably close to the dose that causes harm. Doctors monitor blood levels regularly because even a modest shift upward can cause toxicity, with symptoms ranging from tremor and nausea to confusion, seizures, and kidney damage. Lithium is cleared from the body almost entirely by the kidneys as a free ion, without being broken down by liver enzymes first.1PubMed. Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring Anything that changes how well your kidneys work or how hydrated you are can alter lithium levels in your blood. This is the mechanism that makes the cannabis-lithium combination riskier than the absence of a direct metabolic interaction might suggest.
THC, by contrast, takes a completely different route through the body. After absorption it travels to the liver, where cytochrome P450 enzymes break it down. CBD follows a similar hepatic pathway, primarily through the CYP3A4 and CYP2C9 enzyme families.2PubMed Central. Mechanisms of Action and Pharmacokinetics of Cannabis Because lithium skips the liver entirely and cannabis compounds are processed there, the two substances do not compete for the same metabolic machinery. In pharmacology terms, there is no expected kinetic interaction. But pharmacology terms do not capture the full clinical reality.
The Dehydration and Vomiting Problem
If you smoke cannabis regularly, you may have heard of cannabinoid hyperemesis syndrome, a condition in which chronic users develop recurrent episodes of severe nausea and vomiting. It is not common in casual users, but among people who use heavily and consistently, it is well recognized. Here is why it matters for lithium: when you vomit repeatedly or become dehydrated, your kidneys hold onto more sodium and, along with it, more lithium. Blood levels climb, sometimes quickly. A case report published in BMJ Case Reports described exactly this scenario, in which a three-week period of vomiting related to cannabinoid hyperemesis syndrome lowered the patient’s mood stabilizer serum levels and contributed to the onset of a manic episode.3BMJ Case Reports. Cannabinoid hyperemesis syndrome and the onset of a manic episode
That case illustrates both sides of the danger. Prolonged vomiting can paradoxically cause lithium levels to swing in either direction depending on the circumstances: fluid loss concentrates lithium, but if vomiting prevents someone from keeping their lithium pills down, levels can also drop low enough that mood protection disappears. Either direction is a problem. And because cannabinoid hyperemesis episodes tend to recur in people who continue using cannabis, the instability can become a repeating cycle. Even without full-blown hyperemesis, any bout of dehydration from a long smoking session, a hot day, or simply not drinking enough water can nudge lithium levels in a dangerous direction.
Cannabis and Bipolar Disorder Outcomes
Most people taking lithium are doing so for bipolar disorder, and the evidence on cannabis use in bipolar disorder is consistently unfavorable. A systematic review and meta-analysis found that cannabis use is associated with exacerbation of manic symptoms in people who have already been diagnosed with bipolar disorder.4PubMed. Cannabis use and mania symptoms: a systematic review and meta-analysis That is not a subtle statistical finding buried in subgroup data. It showed up across multiple study designs and populations.
A longitudinal study tracking bipolar patients over twelve months of treatment found that cannabis users had higher levels of overall illness severity, mania, and psychosis compared with non-users over that period.5The Journal of Nervous and Mental Disease. Does Cannabis Use Affect Treatment Outcome in Bipolar Disorder? A Longitudinal Analysis The same study noted that cannabis users also showed less treatment compliance, which introduces a chicken-and-egg problem: does cannabis directly worsen symptoms, or does it worsen them by making people less likely to take their medication? The answer is probably both, but from the patient’s perspective, the distinction is somewhat academic. Either way, outcomes are worse.
Additional research looking specifically at remission rates found that cannabis use was significantly associated with lower remission in bipolar patients. The pattern differed somewhat by sex: in women and patients on mood stabilizers alone, cannabis use was linked to lower remission on depression measures, while in men and patients on certain combination treatments, it was linked to lower remission on mania measures.6PubMed Central. Impact of Cannabis Use on Long-Term Remission in Bipolar I and Schizoaffective Disorder The takeaway is not that cannabis affects men and women differently in some clean way. It is that cannabis use appears to undermine mood stability across the board, with the specific symptom domain varying by individual circumstances.
The Adherence Effect
One of the most consistent findings in the research is that people with bipolar disorder who use cannabis are less likely to take their medications as prescribed. A large analysis of nationwide inpatient data found that cannabis use disorder was significantly associated with medication nonadherence during bipolar disorder hospitalizations, even after adjusting for other variables that might explain the gap.7PubMed. Cannabis use and medication nonadherence in bipolar disorder: A nationwide inpatient sample database analysis Skipping lithium doses is particularly risky because of how the drug works. Lithium needs to stay within a steady range in your bloodstream to be effective, and irregular dosing creates the kind of fluctuations that can trigger both breakthrough mood episodes and rebound symptoms.
Why cannabis use and nonadherence travel together is harder to pin down. Some of it may be self-medication: a person who feels cannabis is managing their symptoms may see less reason to take a prescribed pill. Some of it may involve the cognitive effects of regular cannabis use, including forgetfulness and disrupted routines. And some of it may reflect a broader pattern in which people who use substances are, as a group, less engaged with their treatment plans. Whatever the cause, if you are using cannabis while on lithium, being honest with yourself about whether it is affecting how consistently you take your medication is worth doing.
What About CBD Products?
CBD has become enormously popular, and many people think of it as entirely separate from “weed.” In terms of drug interactions, CBD raises its own set of concerns. Both THC and CBD are substrates and inhibitors of cytochrome P450 enzyme pathways that are involved in breaking down many common psychiatric medications.8PubMed. Drug-drug interactions as a result of co-administering Δ(9)-THC and CBD with other psychotropic agents This matters more for medications that are processed through those enzymes than it does for lithium, which bypasses them. If you are taking lithium alone, a CBD oil is unlikely to change your lithium blood level through enzyme competition.
However, many people on lithium are also prescribed other medications: anticonvulsants like valproate, antipsychotics like quetiapine or olanzapine, antidepressants, or benzodiazepines. Those drugs frequently are metabolized by the CYP3A4 and CYP2C19 pathways that CBD can inhibit. Slowing down the breakdown of those drugs can raise their blood levels, sometimes into ranges that cause side effects. If you are on lithium plus other psychiatric medications, CBD is not the benign supplement the wellness industry suggests. Even if it does not affect the lithium itself, it can alter the levels of your other prescriptions in ways that cascade into problems.
There is also the practical reality that many commercial CBD products contain undisclosed amounts of THC, sometimes above the trace levels listed on the label. Quality control in the CBD market remains inconsistent. If you are managing a narrow-therapeutic-window drug like lithium and believe you are taking “just CBD,” you may be getting more THC exposure than you realize.
Does the Method of Use Change the Risk?
Smoking, vaping, edibles, tinctures, and topicals all deliver cannabinoids differently, and the route of administration does change some aspects of the risk profile. Smoking and vaping produce rapid absorption through the lungs, which means peak blood THC levels hit quickly and the acute psychoactive effects are more intense but shorter-lived. Edibles go through the digestive system and liver first, leading to slower onset but a longer duration of effect and higher levels of the active metabolite 11-hydroxy-THC, which is more potent than THC itself.
For the lithium-specific concerns, the method matters in a few ways. Smoking cannabis carries the general lung health risks of inhaling combustion products, which include chronic bronchitis symptoms and airway irritation. If respiratory illness leads to reduced fluid intake or contributes to dehydration, that circles back to the lithium-level stability problem. Edibles carry a different risk: because onset is delayed, people sometimes take more than intended, leading to stronger and longer episodes of impairment. For someone whose mood stability depends on consistent medication routines, a prolonged period of significant intoxication is not trivial.
Topical CBD products that do not reach the bloodstream in meaningful quantities are the lowest-risk option from a drug-interaction standpoint, though the evidence on how much actually gets absorbed transdermally varies. If your concern is specifically about lithium safety and you are determined to use some form of cannabis product, a topical CBD cream is in a different universe of risk than smoking high-THC flower. But the bipolar-outcome data still applies regardless of route.
Talking to Your Prescriber
Research on patient disclosure of cannabis use paints a somewhat discouraging picture. A study of cannabis-using patients found that while most participants had initiated a conversation about cannabis with their healthcare provider at some point, about a quarter reported that cannabis was never discussed during their care. Healthcare providers initiated the conversation only about 15% of the time. Anticipated stigma was strongly associated with patients never disclosing their cannabis use at all.9PubMed Central. The role of stigma in cannabis use disclosure: an exploratory study
This is a particular problem with lithium because of how closely levels need to be monitored. If your prescriber does not know you are using cannabis, they cannot account for it when interpreting lithium blood levels that come back unexpectedly high or low. They cannot evaluate whether a new symptom is a lithium side effect, a cannabis effect, or an interaction between the two. And they cannot adjust your monitoring schedule to account for the added instability risk. The stigma concern is understandable, but the pharmacological stakes of lithium make nondisclosure genuinely dangerous in a way that might not apply to other psychiatric medications with wider safety margins.
If you feel your prescriber would react poorly, that is worth addressing directly or considering whether a different provider would be a better fit. Psychiatrists who specialize in bipolar disorder are generally familiar with the high rates of cannabis use in their patient population and are more interested in managing the combination safely than in passing judgment. A prescriber who does not know about your cannabis use cannot keep you safe on lithium.
When Lithium Levels Get Checked
Standard lithium monitoring involves periodic blood draws, typically every few months once a stable dose is established, with more frequent checks when starting treatment, changing doses, or when something disrupts the patient’s baseline. If you are using cannabis regularly, your prescriber may want to check levels more often, particularly during periods of heavy use or if you develop any gastrointestinal symptoms. Lithium clearance decreases with aging, which means the margin for error gets thinner as you get older.1PubMed. Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring An older adult using cannabis on lithium has less physiological buffer than a younger one.
Signs of lithium toxicity that you should recognize include persistent nausea, diarrhea, coarse tremor, drowsiness, muscle weakness, slurred speech, and confusion. Mild toxicity symptoms overlap with what many people might attribute to being too high or having a bad reaction to cannabis, which creates a masking problem. If you use cannabis and start feeling unusually shaky, nauseated, or confused, the safer assumption is that something is going on with your lithium level rather than that you just smoked too much. Getting a blood draw is easy and quick. Waiting out a lithium toxicity event is not.
Kidney function tests also become relevant here. Lithium is eliminated entirely through the kidneys, and long-term lithium use itself can affect kidney function over time. If cannabis use is adding any kidney-related stress through dehydration, contaminants, or other mechanisms, regular monitoring of renal function becomes even more important than it already is on lithium alone. Your prescriber should be checking creatinine and estimated glomerular filtration rate periodically regardless, but knowing about your cannabis use helps them interpret those results with the full clinical picture.